Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 8, 2014, Pages 1320-1330

  Patrignani, P ^a   Tacconelli, S ^a   Piazuelo, E ^b   Di Francesco, L ^a   Dovizio, M ^a   Sostres, C ^b   Marcantoni, E ^a   Guillem Llobat, P ^a   Del Boccio, P ^a   Zucchelli, M ^a   Patrono, C ^a,c   Lanas, A ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Acetylsalicylic acid; Antiplatelet drugs; Cyclooxygenase 1; Proteomics

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; BIOLOGICAL MARKER; THROMBOXANE B2;

ACETYLATION; ADULT; ARTICLE; CLINICAL PHARMACOLOGY; DRUG EFFECT; DRUG MECHANISM; ENTERIC COATED TABLET; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; URINARY EXCRETION; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; METABOLISM;

ACETYLATION; AREA UNDER CURVE; ASPIRIN; BIOLOGICAL MARKERS; CYCLOOXYGENASE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; THROMBOXANE B2;

EID: 84905684147     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12637     Document Type: Article

References (32)

1. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: american college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 199s-233s.
2. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991; 68: 11b-5b.
3. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83.
4. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
5. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-50.
6. Dovizio M, Tacconelli S, Sostres C, Ricciotti E, Patrignani P. Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel) 2012; 5: 1346-71.
7. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Investig 2001; 108: 7-13.
8. Ciabattoni G, Pugliese F, Davi G, Pierucci A, Simonetti BM, Patrono C. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 1989; 992: 66-70.
9. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Investig 1982; 69: 1366-72.
10. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-27.
11. Gorog DA, Fuster V. Platelet function tests in clinical cardiology: unfulfilled expectations. J Am Coll Cardiol 2013; 61: 2115-29.
12. Sciulli MG, Renda G, Capone ML, Tacconelli S, Ricciotti E, Manarini S, Evangelista V, Rebuzzi A, Patrignani P. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. Clin Pharmacol Ther 2006; 80: 115-25.
13. Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120: 2586-96.
14. Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 2013; 127: 377-85.
15. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Investig 1975; 56: 624-32.
16. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci USA 2003; 100: 6940-5.
17. Malmstrom J, Lee H, Aebersold R. Advances in proteomic workflows for systems biology. Curr Opin Biotechnol 2007; 18: 378-84.
18. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83: 316-21.
19. Ciabattoni G, Maclouf J, Catella F, FitzGerald GA, Patrono C. Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. Biochim Biophys Acta 1987; 918: 293-7.
20. Zou H, Yuan C, Dong L, Sidhu RS, Hong YH, Kuklev DV, Smith WL. Human cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids. J Lipid Res 2012; 53: 1336-47.
21. Anzellotti P, Capone ML, Jeyam A, Tacconelli S, Bruno A, Tontodonati P, Di Francesco L, Grossi L, Renda G, Merciaro G, Di Gregorio P, Price TS, Garcia Rodriguez LA, Patrignani P. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum 2011; 63: 850-9.
22. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004; 109: 1468-71.
23. Williams FM. Clinical significance of esterases in man. Clin Pharmacokinet 1985; 10: 392-403.
24. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206-11.
25. van Pampus EC, Huijgens PC, Zevenbergen A, Twaalfhoven H, van Kamp GJ, Langenhuijsen MM. Influence of aspirin on human megakaryocyte prostaglandin synthesis. Eur J Haematol 1993; 50: 264-8.
26. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2: 637-43.
27. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, Patrono C. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119: 3595-603.
28. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R, Vazzana N, Del Ponte A, Ferrante E, Martini F, Cardillo C, Morosetti R, Mirabella M, Ghirlanda G, Davi G, Patrono C. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10: 1220-30.
29. Kovács EG, Katona E, Bereczky Z, Homoródi N, Balogh L, Tóth E, Péterfy H, Kiss RG, Edes I, Muszbek LH. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals. Thromb Res 2013; 131: 320-4.
30. Dovizio M, Bruno A, Tacconelli S, Patrignani P. Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res 2013; 191: 39-65.
31. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-doseaspirin in healthy volunteers. Stroke 2006; 37: 2153-8.
32. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012; 9: 259-67.